Danjuma Quarless is Senior Director of AI Therapeutics Innovation at Lilly Ventures, the strategic venture arm Lilly, where he focuses on early-stage investing at the intersection of AI and drug development.
Danjuma’s career spans computational biology, venture capital, and strategic leadership in biopharma. He began his career as a computational biologist, leading analytics for major population genomics initiatives including the UK Biobank and Genomics Finland. He subsequently moved into venture investing as a member of AbbVie Ventures.
Danjuma holds a PhD in Biomedical Sciences from UC San Diego and an MBA from the Kellogg School of Management at Northwestern University.
